N-methyl-D-aspartate receptor antibody production from germinal center reactions: Therapeutic implications
Mateusz Makuch, Robert Wilson, Adam Al-Diwani, James Varley, Anne-Kathrin Kienzler, Jennifer Taylor, Antonio Berretta, Darren Fowler, Belinda Lennox, M Isabel Leite, Patrick Waters, Sarosh R Irani, Mateusz Makuch, Robert Wilson, Adam Al-Diwani, James Varley, Anne-Kathrin Kienzler, Jennifer Taylor, Antonio Berretta, Darren Fowler, Belinda Lennox, M Isabel Leite, Patrick Waters, Sarosh R Irani
Abstract
Introduction: N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis is mediated by immunoglobulin G (IgG) autoantibodies directed against the NR1 subunit of the NMDAR. Around 20% of patients have an underlying ovarian teratoma, and the condition responds to early immunotherapies and ovarian teratoma removal. However, despite clear therapeutic relevance, mechanisms of NR1-IgG production and the contribution of germinal center B cells to NR1-IgG levels are unknown.
Methods: Clinical data and longitudinal paired serum NR1-reactive IgM and IgG levels from 10 patients with NMDAR-antibody encephalitis were determined. Peripheral blood mononuclear cells from these 10 patients, and two available ovarian teratomas, were stimulated with combinations of immune factors and tested for secretion of total IgG and NR1-specific antibodies.
Results: In addition to disease-defining NR1-IgG, serum NR1-IgM was found in 6 of 10 patients. NR1-IgM levels were typically highest around disease onset and detected for several months into the disease course. Moreover, circulating patient B cells were differentiated into CD19+ CD27++ CD38++ antibody-secreting cells in vitro and, from 90% of patients, secreted NR1-IgM and NR1-IgG. Secreted levels of NR1-IgG correlated with serum NR1-IgG (p < 0.0001), and this was observed across the varying disease durations, suggestive of an ongoing process. Furthermore, ovarian teratoma tissue contained infiltrating lymphocytes which produced NR1-IgG in culture.
Interpretation: Serum NR1-IgM and NR1-IgG, alongside the consistent production of NR1-IgG from circulating B cells and from ovarian teratomas suggest that ongoing germinal center reactions may account for the peripheral cell populations which secrete NR1-IgG. Cells participating in germinal center reactions might be a therapeutic target for the treatment of NMDAR-antibody encephalitis. Ann Neurol 2018;83:553-561.
© 2018 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.
Figures
References
- Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti‐N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36.
- Irani SR, Bera K, Waters P, et al. N‐methyl‐D‐aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non‐paraneoplastic disorder of both sexes. Brain 2010;133(pt 6):1655–1667.
- Day GS, Laiq S, Tang‐Wai DF, Munoz DG. Abnormal neurons in teratomas in NMDAR encephalitis. JAMA Neurol 2014;71:717–724.
- Tabata E, Masuda M, Eriguchi M, et al. Immunopathological significance of ovarian teratoma in patients with anti‐N‐methyl‐d‐aspartate receptor encephalitis. Eur Neurol 2014;71:42–48.
- Suh‐Lailam BB, Haven TR, Copple SS, et al. Anti‐NMDA‐receptor antibody encephalitis: performance evaluation and laboratory experience with the anti‐NMDA‐receptor IgG assay. Clin Chim Acta 2013;421:1–6.
- Kreye J, Wenke NK, Chayka M, et al. Human cerebrospinal fluid monoclonal N‐methyl‐D‐aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain 2016;139(pt 10):2641–2652.
- Dale RC, Pillai S, Brilot F. Cerebrospinal fluid CD19 + B‐cell expansion in N‐methyl‐ D‐aspartate receptor encephalitis. Dev Med Child Neurol 2012;55:191–193.
- Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long‐term outcome in patients with anti‐NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–165.
- Rüegg S, Irani SR. The trouble with plasma cells: Getting to the root cause. Neurology 2017;88:340–341.
- Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298:2199–2202.
- Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long‐lived plasma cell. Nat Rev Immunol 2006;6:741–750.
- Halliley JL, Tipton CM, Liesveld J, et al. Long‐Lived Plasma Cells Are Contained within the CD19(‐)CD38(hi)CD138(+) Subset in Human Bone Marrow. Immunity 2015;43:132–145.
- Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391–404.
- Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel‐complex proteins leucine‐rich, glioma inactivated 1 protein and contactin‐associated protein‐2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133:2734–2748.
- Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty‐first century. Nat Rev Drug Discov 2003;2:52–62.
- Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti‐aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011;108:3701–3706.
- Chen D, Gallagher S, Monson N, et al. Inebilizumab, a B cell‐depleting anti‐CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. JCM 2016;5:107–112.
- Nauen DW. Extra‐central nervous system target for assessment and treatment in refractory anti‐N‐methyl‐d‐aspartate receptor encephalitis. J Crit Care 2017;37:234–236.
- Leandro MJ. B‐cell subpopulations in humans and their differential susceptibility to depletion with anti‐CD20 monoclonal antibodies. Arthritis Res Ther 2013;15(suppl 1):S3.
- Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 2014;76:82–94.
- Prüss H, Finke C, Höltje M, et al. N‐methyl‐D‐aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012;72:902–911.
- Castillo‐Gómez E, Oliveira B, Tapken D, et al. All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class. Mol Psychiatry 2017;22:1776–1784.
- Jézéquel J, Johansson EM, Dupuis JP, et al. Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. Nat Commun 2017;8:1791.
- Wilson R, Makuch M, Kienzler AK, et al. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in Neuromyelitis Optica. Brain 2018. doi: .
- Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in 103 patients with faciobrachial dystonic seizures. Brain 2017. doi:
- Krug A, Luker GD, Barchet W, et al. Herpes simplex virus type 1 activates murine natural interferon‐producing cells through toll‐like receptor 9. Blood 2004;103:1433–1437.
- Armangue T, Leypoldt F, Málaga I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014;75:317–323.
- Hacohen Y, Deiva K, Pettingill P, et al. N‐methyl‐D‐aspartate receptor antibodies in post‐herpes simplex virus encephalitis neurological relapse. Mov Disord 2014;29:90–96.
- West JA, Gregory SM, Damania B. Toll‐like receptor sensing of human herpesvirus infection. Front Cell Infect Microbiol 2012;2:122.
- Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015;523:337–341.
- Dabner M, McCluggage WG, Bundell C, et al. Ovarian teratoma associated with anti‐N‐methyl D‐aspartate receptor encephalitis: a report of 5 cases documenting prominent intratumoral lymphoid infiltrates. Int J Gynecol Pathol 2012;31:429–437.
Source: PubMed